T he notion that cardiovascular disease (CVD) remains a major burden to global morbidity and mortality has driven the quest for novel pharmaceutical agents to further reduce CVD risk. In this respect, cholesteryl ester transfer protein (CETP) has gained considerable interest, ever since one of the first descriptions in the 1980s that low CETP levels attributed to deleterious mutations in CETP were associated with longevity, 1 a finding that was later suggested to result from higher high-density lipoprotein (HDL) cholesterol (-C) levels. 2 The role of HDL as a causal determinant in CVD risk, however, has not been established, and HDL-C levels might very well be a risk marker rather than a risk factor. 3,4
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?
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It is striking that 2 decades after the first description of the potential beneficial effects of CETP mutations, the effect of CETP on CVD risk remains inconclusive, and this, by itself, suggests that CETP may not be an attractive therapeutic target for the prevention of CVD. The hypothesis that CETP inhibition would result in CVD risk reduction has been questioned in the past. Fielding and Havel, 5 leading scientists in HDL metabolism, suggested that the increase in HDL-C induced by CETP inhibition could be misleading and in fact not be associated with CVD risk reduction. HDL particles formed on CETP inhibition are cholesteryl ester enriched and may lose their antiatherogenic bioactivity. Apart from insights from HDL metabolism, data derived from animal studies, large prospective human population studies, and clinical trials have generated conflicting results with respect to the role of CETP in CVD risk.
We set out to summarize the published data that cast doubt on CETP as a therapeutic target to lower CVD risk. We focus on data derived from animal and human studies and we emphasize that the data presented are focused on the negative arguments, and these should be balanced against the arguments in favor of CETP inhibition described by Barter et al in this edition of Circulation. 6 a crucial role in the remodeling of HDL particles. Small, lipidpoor pre-β HDL particles are formed by the CETP-induced dissociation of apolipoprotein (apo) A-I from α HDLs, and it is of particular interest that these small pre-β HDL particles have been described to facilitate removal of cholesterol from cells via ABCA1-mediated transport, a pivotal step in antiatherogenesis. Thus, CETP has a crucial role in reverse cholesterol transport, a mechanism by which cholesterol is removed from macrophages and foam cells in the arterial wall for subsequent hepatic clearance. 8 This was further substantiated by more recent studies showing that endogenous CETP activity was positively associated with plasma capacity to mediate free cholesterol efflux from human macrophages. 9 Similar results were shown in the Ludwigshafen Risk and Cardiovascular Health Study, where HDL efflux capacity was measured in 154 patients, who were selected based on either low (n=77) or high CETP concentration (n=77). Low plasma concentrations of CETP were associated with impaired HDL function, suggesting an atheroprotective role of CETP, at least in patients at high risk for coronary artery disease (CAD). 10 The putative beneficial effect of CETP on HDL metabolism and reverse cholesterol transport is counterbalanced by the fact that the amount of cholesterol in proatherogenic apoB-containing lipoproteins decreases concomitantly. In this respect, CETP could be considered a Janus-faced protein in lipid metabolism.
CETP and Animal Models
A number of murine models have been used to investigate the role of CETP in atherosclerosis progression. It is of interest, however, to keep in mind that these models may not be representative of human metabolism, because mice do not express CETP. 11 The results from murine models are conflicting. A number of studies have shown that experimental expression of CETP in murine lipid metabolism results in increased atherosclerosis, 12, 13 whereas other studies have shown that expression of CETP results in protection from atherosclerosis. 14, 15 CETP is expressed in rabbits and in several other animal models, and within these models CETP inhibition has been shown to decrease the extent of atherosclerosis. 16, 17 It is of interest that the CETP inhibitors that were shown to have a beneficial effect on atheroma volume in the rabbit studies showed either no benefit or even deleterious effects in humans (described below). This disconnect between observations from animal and human studies and the nonphysiological conditions of "CETP absence" or overexpression in the different animal models have clearly shown the limited applicability of animal studies to our understanding of the role of CETP in human physiology and pathophysiology.
Studies in Humans With Genetically Defined (Partial) CETP Deficiency
After the initial suggestion that genetically defined CETP deficiency was associated with longevity, 2 a number of studies have been conducted to establish whether severely decreased CETP translates into decreased CVD risk. It is of interest to note that, even in these people who are CETP deficient, it has been extremely difficult to provide conclusive answers in this regard. This is of particular importance because (partial) CETP deficiency might conceptually be regarded as the effect of long-term pharmacological CETP lowering. Zhong et al 18 studied the effect of genetic partial CETP deficiency on the prevalence of CVD and showed that the association depended on HDL-C plasma levels. CETP deficiency was shown not to affect the incidence of CVD in participants with either high or low HDL-C levels, but in contrast at intermediate values between 41 and 60 mg/dL CETP deficiency was associated with an increased incidence of CVD. Similar findings were reported by Hirano et al, 19 who showed that CETP deficiency was not necessarily antiatherogenic, because some patients who were CETP deficient were found to have CVD despite very high HDL-C concentrations. These patients also had consistently low hepatic lipase activity, suggesting that deficiency of both mechanisms for generating lipid-poor apoA-I may substantially affect reverse cholesterol transport and CVD risk. In the Honolulu Heart Study, a large, 7-year prospective analysis composed of 2340 individuals, CVD rates were lowest among men carrying a CETP mutation, but this association did not reach statistical significance. 20 These results are in line with the study by okamura et al, 21 who showed that the extent of coronary calcification was similar in subjects who did and did not carry the CETP D422G gene variant. A similar finding was described by Borggreve et al, 22 who found that a common CETP promoter polymorphism (-629C>A, rs1800775), which causes lower plasma CETP concentrations and contributes to higher HDL-C, was paradoxically associated with an increased incidence of coronary disease in the general population. In a subsequent analysis it was suggested that this counterintuitive finding was related to the cellular cholesterol efflux potential of this gene variant. 23 The association between the common CETP variants (ie, TaqIB [rs708272], I405V [rs5882], and -629C>A [rs1800775]) and CVD risk has been investigated in numerous studies. In a meta-analysis of these studies, CETP genotypes that are associated with moderate inhibition of CETP activity showed a weak inverse association with CVD risk. 24 Most of the studies are composed of white subjects, and it may not be valid to extrapolate these findings to other populations, as was shown by Li et al 25 in a large study conducted in Chinese patients.
Population Studies of CETP Mass and Activity
As a logical extension of the population studies investigating CETP genetics and CVD risk, various prospective population studies measured CETP mass or activity to explore the relationship between these intermediate phenotypes and CVD risk. Given the fact that measurement of CETP activity is time consuming, most large population studies measured CETP mass instead, which is justified by the fact that, under physiological circumstances, CETP mass and activity are strongly correlated. 26 However, pharmacological CETP inhibitors target CETP activity rather than CETP mass, and, importantly, CETP inhibition is not a class effect, because different CETP inhibitor compounds affect CETP activity in different fashions. These aspects must be kept in mind when interpreting the results of observational population studies, and their extrapolation to predict the efficacy of pharmacological intervention studies must be interpreted.
European Prospective Investigation into Cancer (EPIC)-Norfolk was the first large prospective population study where CETP concentrations were measured. 27 The study had a nested case-control design, including 1138 patients who were apparently healthy at baseline but developed CAD during follow-up, and 2237 matched control subjects, who remained free of any CVD. overall, CETP levels did not differ significantly between patients and control subjects (4.0±2.2 versus 3.8±2.1 mg/L; P=0.07). There was, however, a weak positive association between CETP quintiles and CAD risk, such that study participants in the highest CETP quintile had an adjusted odds ratio of 1.43 (95% confidence interval [CI], 1.03-1.99) versus those in the lowest. When the population was split into those with TG levels above versus below the median (1.7 mmol/L), no relationship between CETP levels and CAD risk was observed among those with low TG levels. However, among those with hypertriglyceridemia, there was a strong association between CETP levels and CAD risk (P for linearity=0.02). Since then, this same topic has been addressed in several other prospective studies. one of the first replication studies was an Austrian study that included patients with documented CAD and followed these for recurrent CVD events. 28 All of the patients were treated with pravastatin, and those with hypertriglyceridemia were excluded. Among 1002 patients for whom follow-up was complete, there was an inverse association between CETP quartiles and the risk of CVD events. Interestingly, the risk of CVD events was substantially lower among those in the top versus bottom CETP quartile, despite the fact that these patients had higher LDL-C levels. Thus, in contrast to the EPIC-Norfolk findings, these results suggested an atheroprotective effect of high CETP levels. Borggreve et al 29 performed a substudy of the Prevention of Renal and Vascular Endstage Disease cohort, a study population enriched for microalbuminuria. The substudy was restricted to men without a history of CAD and diabetes mellitus, who were not using lipid-lowering therapy. A total of 111 patients who developed CVD during followup and 116 CVD-free control subjects were selected. The adjusted hazard ratio for CVD per 1-SD increase in CETP was 0.84 (95% CI, 0.69-1.03), also suggesting an inverse association. A substudy of the Framingham Heart Study measured CETP activity instead of CETP concentration. 30 Plasma CETP activity was measured in 1978 apparently healthy study participants. During a mean follow-up of 15.1 years, 320 participants experienced a first CVD event. There was an inverse association between plasma CETP activity and CVD risk; the hazard ratio for CVD was 0.72 (95% CI, 0.57-0.90) for people above versus below the median. A substudy of the Framingham offspring Study included 2679 people without CVD at baseline. 31 Plasma CETP activity was measured in baseline samples, and during a mean follow-up of 10.4 years, 187 participants experienced a first CVD event. In this study, effect modification was observed, suggesting that an inverse association exists between CETP activity and CVD risk among men (hazard ratio, 0.79 [95% CI, 0.64-0.98] per 1-SD increase) but not among women. The Ludwigshafen Risk and Cardiovascular Health study included 3256 study participants who were referred for angiography. 32 Almost 80% had prevalent CHD as documented by angiography, and approximately half of the population was using lipid-lowering therapy. During 7.8 years of follow-up, 474 study participants died of cardiovascular causes. This study also observed an inverse association between CETP concentration and risk of CVD mortality; the hazard ratio was 1.38 (95% CI, 1.05-1.82) for those in the lowest versus highest CETP quartile. The KARoLA (Langzeiterfolge der Kardiologischen Anschlussheilbehandlung) study was a prospective study of 1132 patients with CAD who took part in a cardiovascular rehabilitation program after myocardial infarction or coronary revascularization. 33 Patients were followed for 8 years for the occurrence of all-cause mortality and nonfatal CAD events. In this study, there was no statistically significant association between CETP concentration and the risk of either all-cause mortality or nonfatal CAD events, with respective adjusted hazard ratios of 1.33 (95% CI, 0.77-2.30) and 1.24 (95% CI, 0.75-2.03) for those in the lowest versus highest quartile. The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial enrolled 4162 patients who were hospitalized for an acute coronary syndrome and were randomly assigned to either high-dose or usual-dose statin therapy. 34 Plasma CETP concentration was measured in 3218 patients, of whom 150 experienced a fatal or nonfatal CAD event during the mean follow-up of 1.8 years. In this study, there was also an inverse association between CETP levels and risk of CHD events, with a hazard ratio per 1-SD increase of 0.81 (95% CI, 0.67-0.98). Finally, Seiler et al 35 In summary, several population studies have prospectively investigated the association between CETP levels and risk of CVD events during follow-up. It should be noted that the baseline characteristics of these studies are highly variable, ranging from population studies with apparently healthy people to cohorts of patients with prevalent CAD. Also, baseline lipid levels differed substantially, and the use of statin therapy ranged from 0% to 100% between study populations. These differences may affect the interpretation of the study results importantly because CETP concentration and activity appear to be highly context dependent. For instance, CETP levels are higher among people with elevated LDL-C levels, such as those with familial hypercholesterolemia 36 and among those with high very low-density lipoprotein levels, 37 a phenotype frequently observed in diabetes mellitus. In addition, statin therapy lowers CETP levels, and high-dose statin therapy lowers CETP levels to a larger extent than usual-dose statin therapy. 34, 38 It is therefore difficult to compare the study results of these highly heterogeneous study populations. Nonetheless, of the 9 population studies discussed above, 8 showed a statistically significant or nonsignificant inverse association between CETP levels and CVD risk, suggesting that, across the populations studies, CETP levels appear to be largely beneficial rather than detrimental.
Therapeutic Interventions
Randomized, controlled trials of cardiovascular outcomes in humans are the ultimate test of whether a treatment is useful for CVD prevention, but there are several important considerations about therapeutic interventions of pathways related to HDL metabolism or function that merit consideration. These can broadly be divided into "on-target" effects, that is, predictable dose-dependent effects resulting from CETP inhibition, per se, and "off-target" effects resulting from the effects of the molecules being tested on other systems or on CETP but unrelated to reductions in CETP activity. It is with these factors in mind that we should interpret the results of trials of torcetrapib, dalcetrapib, anacetrapib, evacetrapib, and TA-8995, which are the main CETP inhibitors (CETPis) tested to date or currently undergoing evaluation.
On-Target Effects
Therapeutic inhibition of CETP activity results in the inhibition of heterotypic transfer of cholesterol esters between apoB-containing lipoproteins and HDL particles in a dose-dependent fashion, resulting in an increase in circulating levels of HDL-C and a reduction in LDL-C (Table) . The magnitude of these changes reflect the potency of these agents, and all but dalcetrapib produce significant reductions in LDL-C. CETP inhibition with all of the agents tested to date principally result in an increase in the cholesterol content and the number of the larger HDL2b subfractions. The increases in HDL2b result in an increase of non-ABCA1-mediated cholesterol efflux and, thus, influence total efflux. 39 Indeed, this is what has been observed with the different agents ranging from an increase in total efflux by ≈9% with dalcetrapib to a 2.4-fold increase with anacetrapib. 40, 41 CETPis should also inhibit homotypic transfer of cholesterol esters between HDL subclasses resulting in an increase in lipid-poor pre-β HDL. 42 This was not observed with dalcetrapib in humans, and, consequently, there was no observed increase in ABCA1mediated efflux, because pre-β HDL is the major acceptor of cholesterol via the ABCA1-mediated pathway. 40 Although dalcetrapib had no effect on ABCA1-mediated efflux, anacetrapib and evacetrapib have been shown to increase ABCA1-mediated efflux, as well as non-ABCA1 efflux, which may be a function of the potency of CETPis. 41 Because CETP inhibition also results in an increase in apoA-I, apoA-II, and HDL-related apoE, the functions of the different HDL subclasses are also likely to be affected to differing degrees by the various agents. 42, 43 
Off-Target Effects
Torcetrapib increases blood pressure in humans and in animals that lack CETP, suggesting that these effects are independent of CETP inhibition. In some individuals in the Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events (ILLUMINATE) trial, the effect on blood pressure was particularly marked, with elevations >15 mm Hg recorded, although the average difference was 5.4 mm Hg. 44 Furthermore, in adrenal tissue culture, torcetrapib increases aldosterone production, and in humans it affects bicarbonate, potassium, and sodium levels. Although smaller studies with dalcetrapib did not show a major difference in blood pressure, the large outcomes study, A Study of Ro4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome (dal-oUTCoMES), reported a 0.6-mm Hg higher systolic blood pressure between dalcetrapib and placebo but did not show any adverse effects on aldosterone or other electrolytes. 45 To date, studies of anacetrapib, evacetrapib, and TA-8995 have not demonstrated significant effects on blood pressure, aldosterone, or electrolytes. Finally, there are data to suggest that torcetrapib may bind firmly to CETP and HDL to form a triple complex, which may alter the function of HDL particles. 46 
Table. Effects of CETP Inhibitors on Lipid Parameters Studied in Phase III Clinical Trials
Clinical Outcome Trials
Despite the reductions in LDL-C and increases in HDL-C expected from inhibition of CETP, the ILLUMINATE trial, which tested the efficacy of torcetrapib versus placebo on top of atorvastatin in patients with established CVD, was stopped because of an excess mortality risk of 58% after, on average, 2.5 years. 44 This excess mortality rate included deaths from both vascular and nonvascular disease, including infections and cancer deaths, as well as an excess of nonfatal vascular events. Although the excess vascular deaths could be explained by blood pressure changes, they do not explain the nonvascular effects and could be attributed to on-target or off-target effects of torcetrapib. Three imaging studies were conducted with torcetrapib, which, despite favorable lipid changes with torcetrapib, failed to demonstrate significant benefits on carotid intimamedia thickness or atheroma progression using intravascular ultrasound. [47] [48] [49] When these data are considered in the context of other torcetrapib data, one conclusion is that the favorable changes in LDL-C reduction and improvements in cholesterol efflux were not sufficient to offset the adverse hypertensive effects of torcetrapib among patients with CVD who were receiving background statin therapy. Furthermore, it should be noted that, since the publication of ILLUMINATE, several experimental studies have confirmed the detrimental effects of torcetrapib on HDL function or atherosclerosis, in contrast to the experimental studies published in the pre-ILLUMIATE era, which tended to show positive and promising results for torcetrapib. This observation suggests that experimental studies may not serve as an adequate risk assessment of novel therapies, as the results often serve a self-fulfilling prophecy.
The dal-oUTCoMES trial was stopped for futility after an average of 3 years of follow up. 45 When subgroups such as those with low baseline HDL-C or high LDL-C were assessed, there was no evidence that dalcetrapib had a beneficial effect. Reassuringly there was no adverse clinical safety signal, with no excess risk of vascular or nonvascular deaths or nonfatal events. Imaging trials of dalcetrapib, while demonstrating no adverse safety signal, failed to demonstrate significant improvements in plaque inflammation, volume, or vascular function. 50, 51 Taken together, these data suggest that CETPis could be safe, but, on top of statin therapy treatments that do not alter LDL-C and only improve cholesterol efflux by ≈9%, will not meaningfully reduce CVD events.
There are currently 2 large CVD outcome trials of anacetrapib and evacetrapib underway that have not been stopped yet for futility or safety. Data on both these agents do not suggest that they possess the same adverse safety profile as torcetrapib. If we take the HDL effects aside, the recently completed Improved Reduction of outcomes: Vytorin Efficacy International Trial (IMPRoVE IT) trial has demonstrated the potential of nonstatin lipid modification treatments to reduce CVD risk. We can therefore conclude that LDL-C reduction, per se, by ≈20% even in treated patients with low baseline LDL-C should reduce CVD if the treatment is safe. A major caveat is that, in order for a randomized, controlled trial to detect a significant effect on CVD risk for a treatment that reduces LDL-C to a modest extent, the number of events (a function of trial size, trial duration, baseline risk, and baseline LDL-C) needs to be very large. It is worth remembering that IMPRoVE IT recorded more than 5000 events over ≈9 years with little evidence of benefit in the first year.
There is very little that can be predicted from the CETPiinduced HDL-C changes. In fact, any potential HDL-related CVD benefit might be more related to HDL function rather than HDL-C levels. Both anacetrapib and evacetrapib increase cholesterol efflux to a larger extent than dalcetrapib, but as yet we do not know what level of cholesterol efflux is clinically meaningful, and, although levels of cholesterol efflux might be associated with differences in clinical outcome, we still have no evidence that improving cholesterol efflux translates into reductions in CVD. trials with what is known from the Cholesterol Treatment Trialists Collaboration analyses may simply demonstrate that CETPi, if safe, is just another good way to reduce LDL-C (depicted in the Figure) . on the other hand, if the magnitude of benefit is greater than that predicted by LDL-C change, then it would support the notion that the changes in HDL-mediated cholesterol efflux with these drugs are clinically meaningful. The answer might become available sooner than we think.
Conclusions
The lack of consistent data about the consequences of genetically defined CETP deficiency, the uncertain role of CETP in the randomized, controlled trial process, the variability in lipid parameters in patients treated with the different CETPlowering compounds, and the negative outcomes of previous clinical trials all suggest that there are a lot of reasons to think that CETP lowering will not be a CVD-lowering therapy. At the same time, however, the observed substantial reductions in LDL-C with some CETP inhibitors may be sufficient to overcome whatever negative effects CETPi has on other CVD-related parameters. As a consequence, clinicians could be faced with a situation where a drug has opposing effects on CVD-related parameters but with an overall beneficial outcome in terms of CVD risk reduction.
